Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drugs for the hospital and specialty care markets. Headquartered in Nashville, Tennessee, the company brings a nimble approach to in-licensing and acquiring branded products that address unmet medical needs. Since its incorporation in 1995, Cumberland has built a diversified portfolio spanning analgesics, critical care injectables and gastrointestinal therapies.
The company’s commercial product lineup includes Caldolor® (intravenous ibuprofen) for management of pain and fever in adults, Akovaz® (vasopressin injection) for vasodilatory shock and a prescription antacid program featuring a branded Maalox® product. In addition, Cumberland has advanced several development-stage candidates aimed at niche indications such as pediatric respiratory illness and enhanced delivery formulations. By combining internal research with strategic partnerships, the company seeks to expand its pipeline through both incremental labeling updates and novel molecule development.
Cumberland Pharmaceuticals serves patients and healthcare providers throughout the United States via relationships with major wholesalers, group purchasing organizations and specialty pharmacies. The company’s commercial infrastructure supports hospital, ambulatory surgery center and retail outpatient settings, while its regulatory and quality operations ensure compliance with FDA standards at all manufacturing sites. An emphasis on operational efficiency and targeted marketing allows Cumberland to maintain competitive positioning within its chosen therapeutic segments.
Under the leadership of Chairman and CEO J. Michael Laughlin, Cumberland Pharmaceuticals pursues growth through disciplined product acquisitions and selective internal innovation. Laughlin, along with a management team drawn from leading industry and financial backgrounds, guides the company’s strategic direction and shareholder engagement. With a track record of securing FDA approvals and obtaining favorable reimbursement, Cumberland is dedicated to advancing therapies that improve patient outcomes and deliver long-term value for stakeholders.
AI Generated. May Contain Errors.
Free CPIX Stock Alerts